about
Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B4 in asthmatic childrenIncreased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthmaIon trap liquid chromatography/tandem mass spectrometry analysis of leukotriene B4 in exhaled breath condensate.Role of Leukotrienes and Leukotriene Modifiers in Asthma.Tachykinin-eicosanoid crosstalk in airway inflammation.Isoprostanes: markers and mediators of oxidative stress.Analysis of exhaled breath condensate for monitoring airway inflammation.Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues.Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis.Exhaled leukotrienes and prostaglandins in COPD.Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patientsExhaled breath condensate analysis in patients with COPD.Blood levels of vasoactive intestinal polypeptide in normal and growth retarded fetuses: relationship with acid-base and haemodynamic status.Insights into oxidative stress: the isoprostanes.Leukotrienes, antileukotrienes and asthma.Acute effects of air pollution on pulmonary function, airway inflammation, and oxidative stress in asthmatic childrenAnalysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications.LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation.Pharmacotherapy of asthma: regular treatment or on demand?Leukotriene modifiers for asthma treatment.New perspectives in pharmacological treatment of mild persistent asthma.Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD.Application of 'omics technologies to biomarker discovery in inflammatory lung diseases.Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.Liquid chromatography-mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases.Exhaled nitric oxide as a biomarker in COPD and related comorbidities.Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping.Role of beta-blockers in patients with COPD: current perspective.Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients.Exhaled breath condensate: methodological recommendations and unresolved questions.Toward a personalized pharmacotherapy of respiratory diseases.Measurement of 8-isoprostane in exhaled breath condensate.Diagnosing nonimmediate reactions to penicillins by in vivo tests.Ozone-induced increase in exhaled 8-isoprostane in healthy subjects is resistant to inhaled budesonide.Anaphylaxis increases 8-iso-prostaglandin F2alpha release from guinea-pig lung in vitro.Drugs for chronic obstructive pulmonary disease.Validation of leukotriene B4 measurements in exhaled breath condensate.Increased exhaled 8-isoprostane in childhood asthma.Validation of 8-isoprostane and prostaglandin E(2) measurements in exhaled breath condensate.
P50
Q24816804-10E1D36E-F57A-460A-9D78-162D34253066Q28193535-60E1350A-3E3C-4BE9-A51D-0912752F0A1AQ33432367-70A68073-102B-49A2-96B0-5BF77A05AA8AQ33664150-7C500721-7D52-4F7C-B20B-1FE215952C9FQ34023330-F6056ADE-CA26-42A0-83CC-283B8BDAB29CQ34372985-24345605-9435-4F83-85E7-43E9185C8010Q34635845-950018CC-5943-4153-B30B-C4160D49C2AFQ35113606-74307C60-3A3E-4B68-B837-AEA5F81DEDF2Q35533667-362F89F4-7113-4539-AA55-450F1DE9F061Q35536034-BA81FCF3-2AE0-4A9A-A74F-25E353D4F0E1Q35536727-57DF9605-9C0A-4A87-95BF-F2D688146A67Q36152029-191FE83F-7C68-46F2-BAFD-E7EDE0AF14EBQ36707575-CE7689CD-F65C-4B30-A6A3-DE4A83859AD4Q36754565-3DFE804D-6E59-4752-9E06-FE0BEF020DE8Q37185273-D8C662B1-97C8-4A66-877E-DA79EFC75258Q37185643-0C02FEA0-5ED2-45FA-9FC8-EFF993FD22ADQ37362565-38A86AC2-268C-46DE-A422-8F828FFB6D36Q37398350-FB578E37-6481-48E7-97F9-A59F377A74C6Q37578103-C8E475BC-11D6-4098-B522-A1D5BC9FEEEEQ37808003-A312D780-A95F-4D51-B0B4-9FC392A3296BQ37935268-51003B6C-8A87-46E9-B7A3-269827A7A543Q38042119-B5FBEBBA-4F77-488C-BB72-61FEE8E1F8B1Q38080470-C1030C56-9802-4866-94E3-03526EC0B341Q38081484-8C12B8EA-21FF-47FA-872B-5F08FBDEF8D7Q38198321-C21F5878-A08F-44BC-9F6E-87C8BDCD6A68Q38203516-7A064F99-89C6-4583-9DFA-D3509BF3C9C0Q38245605-B485026B-628F-4F7E-B630-AAC03F270C7AQ38252656-39C97DC1-5EC9-49A0-9C16-8210A4E32470Q39058958-7E8C9B8E-6547-412B-B9A8-0760D3FDB918Q39426025-B700B7A6-798C-4598-B32E-F6AF4E37DF71Q40392502-69190A70-5624-4233-B73A-04744B51F1A7Q42860339-FAB7533F-F172-4EC8-9908-D0925F4093B5Q43194925-45B6C825-D49B-4E44-9DFB-E3F46F16CEECQ44196848-1456C052-7B25-4A41-9B12-B965F446D402Q44207291-9C7F0F15-4FAA-4F82-9A8F-76544DA46585Q44286580-8E2DCA11-4F34-468F-AFD7-DD57DAE05D18Q44328347-120A25CC-B1C6-4A05-9471-98A81C31FE28Q44382506-2E658474-7AFD-4614-9FAC-ACDA24FE3D90Q44508502-93FFA986-1D18-438C-B5DF-FCE22F7D24D4Q44780719-34CD44A9-F4B2-4353-A665-E53E33F614A1
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0001-5589-1750
@en
name
Paolo Montuschi
@ast
Paolo Montuschi
@en
Paolo Montuschi
@es
Paolo Montuschi
@nl
Paolo Montuschi
@sl
type
label
Paolo Montuschi
@ast
Paolo Montuschi
@en
Paolo Montuschi
@es
Paolo Montuschi
@nl
Paolo Montuschi
@sl
prefLabel
Paolo Montuschi
@ast
Paolo Montuschi
@en
Paolo Montuschi
@es
Paolo Montuschi
@nl
Paolo Montuschi
@sl
P214
P244
P5361
P106
P1153
35594020100
P21
P213
0000 0000 3832 2129
P214
P244
n2004121023
P31
P496
0000-0001-5589-1750
P5361
MontuschiPaolo1964-
P569
1964-01-01T00:00:00Z
P735
P7859
lccn-n2004121023